Live Biotherapeutic Products as Cancer Treatments.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37317784.
- Also identified by DOI 10.1158/0008-5472.CAN-22-2626 and PMC identifier 10275495.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Almost every aspect of cancer can be influenced by microbiota including tumor onset, progression, and response to therapy. The increasing evidence of the role of microbiota in human health and disease has reinvigorated the interest in designing microbial products that can affect cancer outcomes. Researchers have made numerous attempts to develop safe, engineered biotherapeutic products for cancer treatment using synthetic biology tools. Despite the progress, only Bacillus Calmette-Guérin is approved for human use. Here, we highlight the recent advances and current challenges in using live bacteria as cancer therapeutics.
Medical subject headings
- Microbiota
- Mycobacterium bovis
- Neoplasms